Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic factors of health care-associated bloodstream infection in adult patients ≥40 years of age.

American journal of infection control·2017
Same author

Addressing Loss of Efficiency Due to Misclassification Error in Enriched Clinical Trials for the Evaluation of Targeted Therapies Based on the Cox Proportional Hazards Model.

PloS one·2016
Same author

Sample size determination for individual bioequivalence inference.

PloS one·2014
Same author

Association of quality of life with laboratory measurements and lifestyle factors in community dwelling older people in Taiwan.

Aging & mental health·2014
Same author

Applications of the bayesian prior information to evaluation of equivalence of similar biological medicinal products.

Journal of biopharmaceutical statistics·2014
Same author

An approximate approach to sample size determination in bioequivalence testing with multiple pharmacokinetic responses.

Statistics in medicine·2014

Related Experiment Video

Updated: Jul 8, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Rethinking statistical approaches to evaluating drug safety.

Jen-pei Liu1

  • 1Statistical Education Center, Division of Biometry, Graduate Institute of Agronomy, National Taiwan University, Taipei, Taiwan. jpliu@ntu.edu.tw

Yonsei Medical Journal
|December 27, 2007
PubMed
Summary

Current drug safety evaluations are insufficient. A non-inferiority approach, focusing on proof of safety, is proposed to demonstrate that new drugs do not present excessive cardiovascular risk, improving drug efficacy assessment.

Related Experiment Videos

Last Updated: Jul 8, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Area of Science:

  • Pharmacology
  • Biostatistics
  • Drug Safety

Background:

  • Traditional methods for evaluating drug safety, often based on proving hazard, are inadequate for determining if a drug poses excessive risk.
  • Existing approaches fail to definitively establish the absence of cardiovascular risk for medications like Vioxx and Avandia.

Purpose of the Study:

  • To propose and validate a non-inferiority approach for assessing drug safety.
  • To demonstrate the superiority of the non-inferiority hypothesis in proving a drug's safety by establishing acceptable risk margins.

Main Methods:

  • Utilized the non-inferiority hypothesis, a concept centered on proof of safety, to assess drug risk.
  • Applied the non-inferiority approach to analyze published data on Vioxx and Avandia, comparing it with traditional proof of hazard methods.

Main Results:

  • Traditional hypothesis testing yielded p-values > 0.05, failing to confirm cardiovascular hazards for Vioxx and Avandia.
  • The non-inferiority approach successfully identified excessive cardiovascular risk associated with Vioxx and Avandia, highlighting its effectiveness.

Conclusions:

  • The non-inferiority approach is a more appropriate and robust method for proving drug safety.
  • This methodology provides a clearer determination of acceptable risk margins for new pharmaceutical products.